Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 Study

REZOR is a multicenter, double-blinded, randomized phase 3 study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). The study included eligible patients from 50 hospitals across China. Those who had been histologically or cytologically confirmed NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation by central laboratory were randomly assigned (1:1) to receive once daily either rezivertinib 180 mg or gefitinib 250 mg. The primary endpoint was progression-free survival (PFS) evaluated by blinded independent central review (BICR), which was significantly superior in the rezivertinib group than the gefitinib group (19.3 versus 9.6 months, HR = 0.48, P <��������������������������������������������������������������������������������������������